Eurofins Scientific Shares Bounce 2.5% and Cross Back Over Moving Averages
The Luxembourg-based bioanalytical testing specialist significantly advances in late Paris trading, erasing the previous day's decline. The stock is among the top gainers on the CAC 40, in an index buoyed by a strong general rebound.
A Rebound That Places the Stock Above Its Three Moving Averages
Eurofins Scientific shares gain 2.33% to €68.62, offsetting a decline of nearly 3% suffered the previous day. The stock ranks among the top gainers on the CAC 40, which is up 0.65% at 8,306 points. This rebound brings the stock above its three moving averages, with a gap of 3.67% over the MM20 (€66.19) and 8.52% over the MM50 (€63.23).
The RSI at 56 remains neutral, while the price approaches the resistance identified at €69.20, which caps the session's gains. Over one month, the stock has risen by 5.76%, a dynamic consistent with the renewed interest observed since the end of June in the stock.
A Session Driven by the CAC 40's Easing After Several Tense Sessions
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The movement is part of a CAC 40 that rebounds sharply after a period marked by geopolitical tensions in the Middle East. The VIX eases to 16.71, down 1.12%, signaling a reduction in caution on the equity markets. On Wall Street, the S&P 500 and Nasdaq are slightly up in session.
The Fed's minutes published yesterday, describing a divided committee but still vigilant on inflation, did not prevent the return of buyers to European stocks. Over twelve months, Eurofins Scientific has posted a gain of 14.98%, a performance that contrasts with the fluctuations experienced in the spring, notably after the April quarterly publication. The next key event to watch will be the release of the semi-annual accounts for 2026.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.